- Home
- GUT vs SVRA Comparison
GUT vs SVRA Comparison
Compare GUT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUT
- SVRA
- Stock Information
- Founded
- GUT 1999
- SVRA 2007
- Country
- GUT United States
- SVRA United States
- Employees
- GUT N/A
- SVRA N/A
- Industry
- GUT Trusts Except Educational Religious and Charitable
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- GUT Finance
- SVRA Health Care
- Exchange
- GUT Nasdaq
- SVRA Nasdaq
- Market Cap
- GUT 527.6M
- SVRA 527.2M
- IPO Year
- GUT N/A
- SVRA N/A
- Fundamental
- Price
- GUT $6.05
- SVRA $3.60
- Analyst Decision
- GUT
- SVRA Buy
- Analyst Count
- GUT 0
- SVRA 8
- Target Price
- GUT N/A
- SVRA $6.63
- AVG Volume (30 Days)
- GUT 176.3K
- SVRA 1.7M
- Earning Date
- GUT 01-01-0001
- SVRA 11-11-2025
- Dividend Yield
- GUT 10.93%
- SVRA N/A
- EPS Growth
- GUT N/A
- SVRA N/A
- EPS
- GUT N/A
- SVRA N/A
- Revenue
- GUT N/A
- SVRA N/A
- Revenue This Year
- GUT N/A
- SVRA N/A
- Revenue Next Year
- GUT N/A
- SVRA N/A
- P/E Ratio
- GUT N/A
- SVRA N/A
- Revenue Growth
- GUT N/A
- SVRA N/A
- 52 Week Low
- GUT $4.60
- SVRA $1.89
- 52 Week High
- GUT $7.38
- SVRA $4.70
- Technical
- Relative Strength Index (RSI)
- GUT 55.30
- SVRA 64.24
- Support Level
- GUT $5.83
- SVRA $3.47
- Resistance Level
- GUT $6.03
- SVRA $3.72
- Average True Range (ATR)
- GUT 0.07
- SVRA 0.18
- MACD
- GUT 0.00
- SVRA -0.03
- Stochastic Oscillator
- GUT 83.46
- SVRA 52.80
About GUT Gabelli Utility Trust (The)
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.